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Abstract: Polycarbonateurethanes (PCU) and polyetherurethanes (PEU) are used for 
medical devices, however their bio- and haemocompatibility is limited. In this study, the 
effect of titaniferous upgrading of different polyurethanes on the bio- and 
haemocompatibility was investigated by endothelial cell (EC) adhesion/proliferation and 
platelet adhesion (scanning electron microscopy), respectively. There was no EC 
adhesion/proliferation and only minor platelet adhesion on upgraded and pure PCU 
(Desmopan). PEUs (Texin 985, Tecothane 1085, Elastollan 1180A) differed in their  
cyto- and haemocompatibility. While EC adhesion depended on the type of PEU, any 
proliferative activity was inhibited. Additional titaniferous upgrading of PEU induced EC 
proliferation and increased metabolic activity. However, adherent ECs were significantly 
activated. While Texin was highly thrombotic, only small amounts of platelets adhered onto 
Tecothane and Elastollan. Additional titaniferous upgrading reduced thrombogenicity of 
Texin, preserved haemocompatibility of Elastollan, and increased platelet 
activation/aggregation on Tecothane. In conclusion, none of the PUs was cytocompatible; 
only titaniferous upgrading allowed EC proliferation and metabolism on PEUs. 
Haemocompatibility depended on the type of PU. 
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1. Introduction 
Polyetherurethanes (PEU) and polycarbonaturethanes (PCU) are used in implantable medical devices 
because of their relatively superior biocompatibility and attractive mechanical properties (high 
elongation capacity, good abrasion resistance, high flexibility, and good biocompatibility for short-term 
usage) [1–5]. However, long-term contact-time of blood with artificial surfaces of medical devices such 
as small-caliber vascular grafts, heart valves, cardiac assist devices, and total artificial hearts increase the 
risk of thromboembolic complications that may lead to treatment failure. Endothelialization of the 
blood-contacting surfaces of medical devices would contribute to an antithrombogenic and 
anti-inflammatory coating that mimics the native lining of blood vessels and the heart [6]. Full coverage 
of polymer surfaces with endothelial cells (ECs) prevents platelet adhesion, thrombus deposition, 
inflammatory cell infiltration, and neointimal formation [7]. Recent studies have shown that rapid 
re-endothelialization or in vivo endothelialization with precursor cells on the surface of devices provides 
an inherent nonthrombogenic potential [8,9]. Thus, the function of endothelialization and 
thromboresistance of medical device (such as cardiovascular devices) surfaces has been regarded as 
important means to improve their respective treatment effect. 
Various strategies in cardiovascular tissue engineering have been used to improve endothelialization 
of polymer surfaces [10]. A recent approach to improve biocompatibility of polymers for biomedical 
applications is titanium (Ti) upgrading [11–14]. Thin films of titaniumcarboxonitride on different 
polymer surfaces maintained flexibility of the polymer, increased wettability of the surfaces and 
supported EC adhesion and sustained anti-inflammatory function of the cells [12,15]. 
In this study, plasma-activated chemical vapour deposition (PACVD) technique was used to upgrade 
different PEUs and PCUs with a Ti-based layer [16]. The cyto- and haemocompatibility of titaniferous 
upgraded PUs were tested under static culture conditions. 
2. Results 
2.1. XPS of Polyurethanes after Titaniumcarboxonitride Upgrading 
The maximal surface atom fraction of titanium (Ti) was between 19% and 21%, which decreased 
toward the inner part of the polyurethane (with increasing sputter time). Figure 1 presents the curve 
progression of pure (Figure 1a) and titaniferous upgraded PU_2 (Figure 1b). XPS analysis of titaniferous 
upgrading of the other polyurethanes provided similar curve progressions. The concentration of carbon 
atoms (C), the main component of polyurethane, increased with penetration depth. The upgraded surface 
was composed of carbon (C), titanium (Ti) and nitrogen (N), each being a component of the upgrading 
reagent Tetrakis (dimethylamino)titanium (Ti[N(CH3)2]4). When exposed to air during storage, the 
upgraded surface absorbs oxygen (O). During plasma deposition, no oxygen was present.  
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Figure 1. Representative XPS of (a) pure and (b) titaniferous upgraded PU_2. Surface 
characteristics show a homogenous composition of carbon (C), oxygen (O), titanium (Ti) 
and nitrogen (N) on titaniferous upgraded ti_PU_2 and pure PU_2 (control). The spectrum 
of the upgraded surface which can be regarded lies in the measuring range between 30 and 
1000 sputtering seconds. 
 
(a) (b) 
2.2. Cytocompatibility of Pure and Titaniferous Upgrading PUs Using EC Adhesion 
As shown in Figure 2, adherence of ECs depended on the type of PU. While ECs avoided cell 
adhesion onto polycarbonate-based PU (PU_4), the cells preferred adherence onto polyether-based PUs. 
Highest cell density was documented for PU_1 (90% ± 1% of TCP), followed by PU_2 (64% ± 15% of 
TCP; *, p ≤ 0.05) and PU_3 (45% ± 22% of TCP; *, p ≤ 0.05). Only titaniferous upgrading of PU_3 
tended to improve EC adhesion (not significant). 
Cell proliferation was an essential criterion for cytocompatibility of different biomaterials (Figure 3). 
While the count of ECs cultured on TCP increased significantly from day 3 to 7 after seeding (by a factor 
of 2.4 ± 0.7, p ≤ 0.001), cell density remained unchanged over the whole study period for cells seeded 
onto all pure PUs. Additional titaniferous upgrading initiated cell proliferation but to a lesser extent than 
for cells on TCP. No cell proliferation was observed for cells seeded onto titaniferous upgraded 
polycarbonate-based PU (PU_4). Seven days after seeding, cell number on titaniferous upgraded 
polyether-based PUs was significantly higher than on pure PUs (each test sample, #, p ≤ 0.001). However, 
maximum cell density was significantly lower than for cells cultured onto TCP (ti_PU_1, factor 1.7 ± 0.7, 
p = 0.002; ti_PU_2, factor 1.2 ± 0.4, p = 0.015; ti_PU_3, factor 1.3 ± 0.3, p = 0.056) (Figure 3a). 
Nevertheless, ECs cultivated for seven days on PEUs formed a confluent monolayer (Figure 3b). Similar 
data were documented using a cell viability assay (MTS-assay). On day 7 after seeding, the MTS 
absorbance of cells cultured onto titaniferous upgraded PEUs tended to be higher than for cells on pure 
PEUs (ti_PU_1 vs. PU_1, 0.15 ± 0.03 vs. 0.14 ± 0.11, not significant; ti_PU_2 vs. PU_2,  
0.20 ± 0.09 vs. 0.08 ± 0.05, p=0.091; ti_PU_3 vs. PU_3, 0.15 ± 0.10 vs. 0.0 ± 0.05, not significant). 
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Figure 2. An in vitro study (n = 4) over 24 hours about adhesion of human endothelial cells 
seeded onto different PUs. Cells were seeded (20,000 cells per 0.3 cm
2
) onto test samples 
made of polyetherurethanes (PEU) (PU_1, PU_2, PU_3) and polycarbonateurethanes (PCU) 
(PU_4) without and with titaniferous upgrading (ti_PU) and tissue-cultured polystyrole 
(TCP) for 24 hours. Data are presented as mean with standard deviation. Statistical analysis 
included comparison of test materials with TCP (*, p ≤ 0.05).  
 
Figure 3. An in vitro study (n = 16) over seven days regarding proliferation of human 
endothelial cells seeded onto different PUs. (a) Cells were seeded (5000 cells per 0.3 cm
2
) 
onto test samples made of PEU (PU_1, PU_2, PU_3) and PCU (PU_4) without and with 
titaniferous upgrading (ti_PU) and tissue-cultured polystyrole (TCP). Cell counts were 
analyzed on day 3, 5 and 7 after seeding. Data are presented as median (25/75th percentile). 
Statistical analysis included increase in cell count from day 3–7 (#, p ≤ 0.001). Cell count on 
day 7 was highest for TCP and significantly lower for ti_PU_1 (p = 0.002), ti_PU_2  
(p = 0.015), ti_PU_3 (p = 0.056); (b) on day 7 after seeding cells formed a confluent 
monolayer onto PEUs. One representative sample presented CD31-FITC stained EC.  
 
(a) 
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Figure 3. Cont. 
 
(b) 
Cultivation of ECs on the surface of different pure and titaniferous upgraded PUs could initiate an 
inflammatory activation of ECs. After seven days, a low proportion of PBMCs adhered onto the surface 
of ECs cultured on TCP. Fluorescence intensity increased significantly with respect to PBMC adhesion 
onto ECs cultured on different PUs. Assuming that PBMCs adhered only on activated ECs and 
considering differences of EC density on day 7 after seeding (Figure 3), fluorescence intensity per EC 
increased significantly for all cells cultured onto different PU test samples (Figure 4).  
Figure 4. Activation of endothelial cells (EC) cultured on different PUs. ECs (n = 8) were 
cultured for 7 d (Figure 2), and incubated with Calcein-AM-stained PBMCs as described in 
Materials and Methods. The fluorescence intensity describes the amount of PBMCs that 
adhered on the surface of a single EC. Data are presented as median (25/75th percentile). 
The fluorescence intensity per EC increased significantly for all cells cultured onto 
different PU test samples (*, p ≤ 0.05). 
 
2.3. Haemocompatibility of Pure and Titaniferous Upgraded PUs Using Platelet Adhesion Test 
Representative SEM photographs of platelet adhesion onto PU test samples were shown in Figure 5. 
There was no platelet adhesion onto pure and titaniferous upgraded polycarbonate-based (PU_4) PUs 
(Figure 5G,H). Pure PEUs differed in their haemocompatibility. While adherent platelets onto PU_1 
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formed a dense network of collagen, PU_2 and PU_3 allowed minor platelet adhesion with single cells 
and small aggregates (Table 1). 
Figure 5. Morphologies of adherent platelets on the surface of different PUs. Isolated 
platelets were incubated with pure and titaniferous upgrading PUs. Representative SEM 
photographs of adherent platelets (3000× magnification) on (A) PU_1; (B) ti_PU_1;  
(C) PU_2; (D) ti_PU_2; (E) PU_3; (F) ti_PU_3 presented different cell density on the 
surface of the test samples; (G) PU_4 and (H) ti_PU_4 were more or less free of platelets. 
Arrows indicate small cracks in the titaniferous layers. 
 
Materials 2014, 7 629 
 
Adherent platelets showed a dendritic shape with pseudopodia of varying lengths (tended to be longer 
on PU_2). Titaniferous upgrading of PU_1 reduced extensive platelet adhesion. Nevertheless, small 
clusters of aggregated platelets were detected that indicate the potential risk of platelet 
adhesion/aggregation on this surface. Titaniferous upgrading of PU_2 caused extensive platelet 
aggregation and network formation. In contrast, titaniferous upgrading of PU_3 did not affect the 
platelet adhesion. Cell density and shape was similar to pure PU_3 (Table 1, Figure 5). Finally, pure and 
titaniferous upgraded PU (PU_4) was thromboresistant; only few platelets adhered onto the surface, 
characterized by small and round cell morphology (Table 1, Figure 5). 
Table 1. Haemocompatibility of pure and titaniferous upgraded polyurethanes. 
Test 
samples 
Product 
name 
n 
Cooper’s 
classification [17] 
Cell density 
(cells per µm
2
) 
p-value 
Length of 
pseudopodia (µm) 
PU_1 Texin® 985 4 3–4 >60 – collagen network 
Ti_PU_1 – 4 2 6 ± 6 0.029 2.6 ± 0.9 
PU_2 Tecothane® 4 2 9 ± 1 – 3.4 ± 1.4 
Ti_PU_2 – 4 4 >60 0.057 collagen network 
PU_3 Elastollan® 5 3 8 ± 8 – 2.2 ± 0.9 
Ti_PU_3 – 5 2 13 ± 3 0.421 2.7 ± 0.9 
PU_4 Desmopan® 4 1* 0.3 ± 0.3 – 0.3 ± 0.4 
Ti_PU_4 – 4 1* 0.4 ± 0.4 0.786 no pseudopodia 
Ti_PU, titaniferous upgraded polyurethane (PU); Cooper’s classification see Section 4.3; * only a few adherent 
cells were detectable. 
3. Discussion 
Titaniferous upgrading using PACVD technique facilitated proliferation of endothelial cells onto 
PEUs but not PCUs. Titaniferous upgrading of Texin
®
 985 reduced platelet adhesion. 
The great importance of EC coverage of synthetic surfaces in tissue engineering has been shown  
in vitro [18–21] as well as in animal studies [9,22]. One way to improve endothelialization of 
cell-repellent surfaces such as PU was nanoupgrading with titaniumcarboxonitride using PACVD 
technology [12,23]. In a previous study, we demonstrated poor adhesion and proliferation of human ECs 
and mouse fibroblasts (L929) on different types of pure PEUs [23]. Now, we could show that 
titaniferous upgrading initiated EC proliferation and increased metabolic activity to form a confluent 
monolayer on the surface of different types of PEU. The improved proliferative activity of ECs based on 
the increased wettability of titaniferous upgraded PEUs as already shown in an earlier study [12]. 
However, the effectiveness of endothelialization was limited compared to TCP. One reason might be the 
presence of small cracks in the titanium layer as presented in high-resolution SEM figures (Figure 5, 
inserts). These cracks were free of titanium (data not shown) and presented the pure PEUs to the ECs. In 
contrast, neither upgraded nor pure PCU allowed EC proliferation. Therefore, we suspect that EC 
seeding onto this type of PCU is inappropriate for enhancing biocompatibility of medical devices. The 
beneficial properties of PCU—the reported resistance to oxidative biodegradation [24–26]—for 
long-term biomedical usage could thus not be exploited. Only biofunctionalization of PCUs with the 
bioactive RGD peptide, which is a functional domain of fibronectin, allowed relatively rapid 
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endothelialization with endothelial progenitor cells in an animal model [27]. Therefore, additional 
surface modifications of PCU are necessary to improve the potential of in situ endothelialization 
cardiovascular prostheses. 
In addition to the increased proliferative activity of human ECs being in direct contact with 
titaniferous upgraded PEUs, the surface properties of upgraded PEUs initiated an activation of adherent 
ECs. The use of a functional test—the adhesion of PBMCs—indicated the presence of activated ECs on 
the surface of pure and upgraded PEUs. Independent of the type of PU and upgrading process, all 
adherent ECs bound significantly more PBMCs than ECs on the reference material (TCP). This was in 
contrast to our previous in vitro study [12]. Nanoupgrading with titaniumcarboxonitride of different 
polymer materials (PU, silicon, polypropylene, polytetrafluoroethylene, polyethylene terephthalate) did 
not affect proinflammatory response of human ECs [12]. Inconsistent results might be due to the large 
variability of PU materials showing different surface properties [3]. Of particular importance is the 
surface energy of PUs (controlled by the chain structures of PU, polar interactions and hydrogen bonds 
between their soft and hard segments), which affects its hydrophobicity [28]. The relevance of EC 
activation after contact with different biomaterials was already shown in experimental studies.  
Cenni et al. [29] reported an upregulation of E-selectin by human umbilical vein ECs (HUVEC) cultured 
on knitted Dacron in contrast to HUVECs cultured on pyrolytic carbon-coated polyethylene 
terephthalate and woven Dacron. Furthermore, Margiotta et al. [30] presented an increased expression 
of ICAM-1 by ECs grown on Dacron and expanded Teflon. In summary, each surface modification of 
polymers required individual bio- and cytocompatibility testing to exclude biomaterial induced 
inflammatory activation of ECs that might affect the success of cardiovascular devices. 
Because thromboembolic formation is initiated by platelet adhesion to foreign materials [31], we 
investigated whether titaniferous upgraded PUs would decrease platelet adhesion. The type of PCU used 
in the present study prevented platelet adhesion. Titaniferous upgrading did not affect its anti-thrombotic 
properties. A polycarbonate-based PU (not further characterized) used by Weisenberg and Mooradian [32] 
demonstrated platelet adhesion consisting of round shaped and less spreading platelets—a marker of 
non-activated platelets. They concluded that silicon-based biomaterials may be more reactive to platelets 
and therefore more thrombogenic than PCU [32]. In another in vitro study, specified 
PCUs—Carbothane, Chronoflex, Corethane 80A and Corethane 55D—demonstrated some level of 
hemolysis after direct contact with blood for a 2 h period [33]. However, platelet adhesion in an ex vivo 
circuit was only significantly increased for Carbothane. In the same study, the PEUs (Tecoflex, 
Tecothane) recorded a low level of platelet adhesion. In our study, there were variations in the degree of 
platelet adherence on the surface of pure PEUs: While Texin (PU_1) was completely covered with a 
collagen network of aggregated and activated platelets, Tecothane (PU_2) presented a lower density of 
adherent platelets. However, the dendritic shape of adherent platelets with long pseudopodia indicated 
higher activation status of the platelets compared to Elastollan (PU_3). Titaniferous upgrading reduced 
platelet adhesion onto Texin (PU_1). Nanoupgrading with titanium using PACVD technique was 
already used in animal models to demonstrate its improved haemocompatibility. Implantation of 
titaniferous upgraded pump chambers made of PTFE from biomechanical hearts [34] in goats reduced 
thrombogenicity of the synthetic surface. Only eight weeks after implantation, a thrombus was formed 
on the luminal surface of the pure pump chambers resulting in a decrease of the pumping capacity. In 
contrast, titaniferous upgrading of the pump chambers prolonged their lifespan without detection of 
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thrombotic depositions (Guldner, personal notification). Furthermore, titanium upgrading of clinically 
approved cardiovascular patches made of expanded polytetrafluoroethylene (ePTFE) enhanced the 
retention of umbilical cord tissue-derived mesenchymal stem cells, thus offering a potential cell reserve 
for repair of the damaged myocardium [35]. Finally, titanium nanoupgrading on glutaraldehyde-fixed 
bovine pericardium prevented immunorejection and created the first self-seeded glutaraldehyde-fixed 
biological heart valve within the circulation under arterial pressure [36,37].  
The increased thrombogenicity of Tecothane (PU_2) after titaniferous upgrading was surprising. The 
causal relationship for this finding is unknown. It could be speculated that titaniferous upgrading of 
Tecothane (PU_2) affected the surface characteristics dramatically and favoured platelet adhesion. In 
contrast, coverage of the surface of Texin (PU_1) with the titaniumcarboxonitride-layer increased its 
thromboresistance. Nevertheless, small clusters of aggregated platelets were detected that indicated the 
potential risk of platelet adhesion/aggregation on this surface. Finally, only the direct blood contact in an 
animal model might bring light into the dark of improvement of haemocompatibility after  
titaniferous upgrading. 
4. Experimental Section 
4.1. Test Samples and Titanium Upgrading 
Discs (area, 0.3 cm
2
) of different types of polyether- (PU_1–3) and polycarbonate-based (PU_4) 
polyurethane foils (Table 2) were upgraded with a thin (50–80 nm) titaniumcarboxonitride layer (tiPU) 
by plasma-activated chemical vapour deposition(PACVD) (pfm medical titanium, Nürnberg,  
Germany) [12]. This upgrading technology (patent number EP 0 897 997 B1) used a precursor 
(Tetrakisdimethylamidotitanium, Ti(N(CH3)2)4) that is transferred into the gas phase and brought into 
the reactor by a carrier gas, such as hydrogen gas, under vacuum conditions. The precursor reacts with 
the substrate creating a resistant layer. Physical plasma is able to supply the substrate with high energy 
while the temperature during deposition remains low (approximately 30–35 °C). Within nonthermal 
plasma with high electron temperatures but with neutrons and ions at room temperature, only electrons 
can follow a quickly changing electrical field with a typical frequency of 13.56 MHz [16,38]. Thickness 
of the titaniferous layer depends on the plasma activation time. The elements and their composition of 
the titaniferous upgraded polyurethane (ti_PU) membranes were analyzed by XPS (X-ray Photoelectron 
Spectroscopy; Sage 100, SPECS, Berlin, Germany). Pure and upgraded test samples were washed with 
ethanol (70%) and sterile isotonic phosphate buffer saline (PBS), placed on the bottom of wells from a 
96-well microplate (Nunc
®
, Wiesbaden, Germany), and fixed with sterile steel rings. Tissue-cultured 
polystyrol (TCP) (Nunc
®
) was used as a reference.  
Table 2. Overview of used polyurethanes. 
Test samples Type Product Manufacturer 
PU_1 PEU Texin® 985 Bayer, Leverkusen, Germany 
PU_2 PEU Tecothane® TT1085 Lubrizol, Wickliffe, OH, USA 
PU_3 PEU Elastollan® 1180A BASF, Ludwigshafen, Germany 
PU_4 PCU Desmopan® BASF, Ludwigshafen, Germany 
PEU, polyether-based polyurethane; PCU, polycarbonate-based polyurethane. 
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4.2. EC Adhesion and Proliferation—A Measure of Cyto- and Biocompatibility 
Isolation and cultivation of human saphenous vein EC (HSVEC) was described in detail earlier [12]. 
Informed consent was obtained from cell donors and the protocol was approved by the local human 
ethics committee (No. 99/133). EC were cultured in growth medium with serum (GMS, Medium 199, 
10% fetal calf serum, L-Glutamine (PAA Laboratories, Pasching, Austria), Supplement Pack 
(PromoCell, Heidelberg, Germany)) at 37 °C under 5% CO2. For EC adhesion tests, EC were seeded at a 
density of 66,000 cells per cm
2
 onto fibronectin-coated (10 µg/ml; Merck, Darmstadt,  
Germany) test samples or TCP and incubated for 24 h. Fibronectin-coating secured improved cell 
adhesion [15]. For EC proliferation tests, 17,000 HSVEC per cm
2
 were seeded onto fibronectin-coated 
test samples for 7 d. Cells were fed with fresh GMS on day 3 and 5 after seeding, harvested on  
days 3, 5 and 7 by addition of trypsin/EDTA (Promocell), and counted with an automatic cell counter 
(CASY-TTC, Roche, Mannheim, Germany) that allowed differentiation between live and  
dead cells. Furthermore, cell viability of EC was measured on day 7 using the MTS 
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide] test (Promega, Madison, I) according 
to manufacturers’ instructions. In a subset of experiments, EC were stained with a mouse-monoclonal 
anti-human CD31-FITC (fluorescein isothiocyanate) antibody (DAKO, Glostrup, Denmark) and 
visualized with a fluorescence microscope (Leica DMRBE, Biberach, Germany). 
4.3. Platelet Adhesion—A Measure of Haemocompatibility 
Scanning electron microscopy (SEM) was used to measure platelet adhesion and to visualize shape 
changes of adherent platelets as a marker of activation. Briefly, human citrated venous blood was drawn 
from healthy male volunteers with written consent in accordance with the institution’s ethical guidelines 
(No. 10-101-0159). Blood samples were centrifuged (300 g, 15 min, 37 °C). Platelet-rich plasma (PRP) 
was isolated from the interphase, transferred into a polypropylene syringe containing 10% aqueous 
citrate dextrose (80 mg citrate, 120 mg glucose monohydrate in 10 mL H2O), and centrifuged again to 
discharge serum (PPP, platelet poor plasma). Platelets were counted using a Neubauer Haemocytometer. 
PRP (50 µL; 5 × 10
7
 platelets per 0.3 cm
2
) was coincubated with test samples (30 min, 37 °C, 5% CO2). 
After rinsing, the specimen were fixated in 2.5% glutaraldehyde in 0.1 M cacodylate buffer at 4 °C; post 
fixation was performed in 1% osmium tetroxide followed by critical point drying. After drying, the 
specimens were mounted on aluminum stubs (Ted Pella, Redding, CA, USA) with carbon disks (Ted 
Pella) and colloidal quick drying silver paint (Ted Pella). Then, the specimens were coated with 
gold-palladium, by means of a sputter-coater (E-5100, Polaron Equipment, Watford, England) at 10 mA 
for 1 min. The PU test samples were observed under an environmental, variable pressure Field Emission 
Scanning Electron Microscope (FESEM) (FEI Quants 400FEG, Philips, Eindhoven, The Netherlands) at 
an accelerating voltage of 5 kV and a working distance of 12–13 mm. The morphologies of adhered 
platelets were characterized by and classified according to platelet shape [17,39] (1, round or discoid, no 
pseudopodia present; 2, dendritic, early pseudopodial, no flattening; 3, spread dendritic, more 
pseudopodia flattened, partial hyaloplasm between pseudopodia; 4, fully spread, hyaloplasm fully 
spread, no distinct pseudopodia, formation of collagen networks). 
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Before the platelet adhesion tests were performed, the activation status of all PRP samples were 
tested using flow cytometry. A small proportion of PRP was double-stained with 
fluorochrome-conjugated monoclonal anti-CD41-FITC and anti-human CD62P-APC (BD Biosciences, 
Erembodegem, Belgium) (24 h at 4 °C) and analyzed. Only PRP preparations with less than 5%–10% 
CD41+CD62P+ platelets were used for platelet adhesion tests. 
4.4. Adhesion of PBMC onto ECs Cultured on Different PUs 
Fresh venous blood from healthy adult volunteers was collected in EDTA tubes. Peripheral blood 
mononuclear cells (PBMC) were isolated using Ficoll-Paque™ (1.073 g/mL; GE Healthcare, Uppsala, 
Sweden) [40]. PBMCs were stained with calcein-acetomethylester (calcein-AM; stock solution:  
1 mg/mL in DMSO; working concentration: 5 µg/mL; Molecular probes, Eugene, OR, USA), counted 
(Neubauer Haemocytometer), resupended in GMS (2 × 10
5
 PBMCs per well), and colocalized with 
endothelialized test samples for 30 min. Test samples were washed with phosphate buffer saline (PBS), 
lysed with 1% triton X-100 (Biorad, Hercules, CA, USA), and frozen overnight before the fluorescence 
intensity (385/535 nm) was measured using the Wallac 1420 Victor 3TM Plate Reader (PerkinElmer, 
Boston, MA, USA). The fluorescence intensity of lysed cells identified bound PBMCs per test sample area. 
4.5. Statistics 
Data were presented as mean ± standard deviation (SD), and analyzed with the 
Wilcoxon-Signed-Rank-Test (Sigma-Stat, SPSS, Chicago, IL, USA) after passing the Friedman-Test 
(Sigma-Stat). p-values ≤ 0.05 were considered significant. All analyses in the static cell culture were 
done with six different cultures in quadruplicate. The amount of experiments in the dynamic setting was 
specified in the respective data presentation.  
5. Conclusion 
Titaniferous upgrading of commercially available biomedical-grade PUs using PACVD technique is 
a suitable method to improve cytocompatibility of blood-contacting devices. The thin Ti(C,N,O) layer 
promotes EC proliferation onto PEU but not onto PCU. Furthermore, the haemocompatibility of 
titaniferous surfaces is very inconsistent. 
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